Evidence map›Paper›PMID 18274695›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2008

Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women.

F A Syed, M J Oursler, T E Hefferanm, J M Peterson, B L Riggs, S Khosla

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 198 citations in OpenAlex.

  1. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.The Journal of clinical endocrinology and metabolism · 2013
    Trial
  2. Trial
  3. Trial
  4. Effects of risedronate on bone marrow adipocytes in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011
    Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

F A SyedEndocrine Research Unit and Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA.
M J Oursler
T E Hefferanm
J M Peterson
B L Riggs
S Khosla
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US

Funding

SEX STEROIDS, GROWTH FACTORS, &BONE CELL FUNCTIONP01AG004875 · NIA · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 1985 to 2019
$30.8M
Estrogen Regulation of the Bone Marrrow AdipocyteR01AG028936 · NIA · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2006 to 2010
$1.7M
NIA NIH HHS P01 AG004875NIA NIH HHS R01 AG028936
6 · The paper itself

Abstract

unlabelledOne-year treatment of osteoporotic postmenopausal women with transdermal estrogen resulted in significant decreases in bone marrow adipocyte volume and prevented increases in adipocyte number as compared to placebo-treated controls. Estrogen treatment also prevented increases in mean adipocyte size over 1 year.

introductionAging is associated not only with bone loss but also with increases in bone marrow adipocytes. Since osteoblasts and adipocytes are derived from a common precursor, it is possible that with aging, there is a preferential "switch" in commitment of this precursor to the adipocyte over the osteoblast lineage. We tested the hypothesis that the apparent "age-related" increase in marrow adipocytes is due, at least in part, to estrogen (E) deficiency.

methodsReanalysis of bone biopsies from a randomized, placebo-controlled trial involving 56 postmenopausal osteoporotic women (mean age, 64 years) treated either with placebo (PL, n = 27) or transdermal estradiol (0.1 mg/d, n = 29) for 1 year.

resultsAdipocyte volume/tissue volume (AV/TV) and adipocyte number (Ad#) increased (by 20%, P < 0.05) in the PL group, but were unchanged (Ad#) or decreased (AV/TV, by -24%, P < 0.001) in the E group. E treatment also prevented increases in mean adipocyte size over 1 year.

conclusionsThese findings represent the first in vivo demonstration in humans that not only ongoing bone loss, but also the increase in bone marrow adipocyte number and size in postmenopausal osteoporotic women may be due, at least in part, to E deficiency.

Indexed as

AdipocytesAdministration, CutaneousAgedAnthropometryBiopsyBone DensityBone Marrow CellsCell CountCell SizeEstradiolEstrogen Replacement TherapyFemaleHumansLeptinLipidsMiddle AgedEstradiolLeptinLipids

Identifiers

PMID18274695
PMCPMC2652842
OpenAlexW2003197644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.